|
Westat biostatisticians
are experienced in identifying and addressing the relevant
statistical issues and developing a detailed analysis
plan early in the clinical development stage. This approach
assures an appropriate study design, so that sample
size requirements, patient selection, and statistical
analysis plans are in line with the clinical development
schedule. In collaboration with FDA reviewers, Westat
has developed new, innovative statistical designs and
analysis methods that improve the efficiency and cost effectiveness
of clinical programs. |
